Company: HCWB
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-058961
Chunk: 25

Company: HCW Biologics Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 25
---
 our board of directors. OUR BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” THE NOMINEES FOR THE ELECTION OF THE CLASS I DIRECTORS SET FORTH IN THIS PROPOSAL ONE. Continuing Directors The directors who are serving for terms that end following the Annual Meeting and their ages, occupations and lengths of service on our board of directors as of April 22, 2025 are provided in the table below and in the additional biographical descriptions set forth in the text below the table.

| Name                 |     | Age |     | Position                                      | Director Since |
| Class II Directors:  |     |     |     |                                               |                |
| Lisa M. Giles(1)(2)  |     |  66 |     | Director                                      | October 2021   |
| Rick S. Greene(1)(2) |     |  60 |     | Chair of Audit Committee and Director         | May 2021       |
| Class III Director:  |     |     |     |                                               |                |
| Hing C. Wong, Ph.D.  |     |  71 |     | Founder, Chief Executive Officer and Director | April 2018     |

(1) Member of our audit committee (2) Member of our compensation committee

<div align='center'>16</div>

TABLE OF CONTENTS

Lisa M. Gileshas served on our board of directors since October 2021. Ms. Giles founded and has served as the Managing Director and Chief Executive Officer of Giles & Associates Consultancy, Inc. (GAC), a consulting firm in the life sciences industry and academic medical centers, since 2000. In addition to HCW Biologics, Ms. Giles currently serves as a member of the board of directors for Milestone Pharmaceuticals and the Northwestern Memorial Health System Foundation Board. She previously served as a member of the board of directors for GenMark Diagnostics from 2015 to 2021; Durata Therapeutics, Inc. from 2012 to 2014, and Intranasal Therapeutics, Inc. from 2005 to 2006. She also was the Founder and Chief Executive Officer of Optivara, Inc. a sister company to GAC, from 2013 to 2019. Prior to founding GAC, Ms. Giles was the Vice President of strategy development at G.D. Searle Pharmaceutical, a division of Monsanto, and held various leadership roles with Abbott Laboratories. Ms